**AGE/ GENDER** : 35 YRS/FEMALE **PATIENT ID** : 1727178

COLLECTED BY : REG. NO./LAB NO. : 122501180004

 REFERRED BY
 :
 REGISTRATION DATE
 : 18/Jan/2025 09:26 AM

 BARCODE NO.
 : 12506569
 COLLECTION DATE
 : 18/Jan/2025 09:27AM

**CLIENT CODE.** : P.K.R JAIN HEALTHCARE INSTITUTE **REPORTING DATE** : 18/Jan/2025 01:39PM

**CLIENT ADDRESS**: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit Biological Reference interval

# SWASTHYA WELLNESS PANEL: 1.2 COMPLETE BLOOD COUNT (CBC)

### **RED BLOOD CELLS (RBCS) COUNT AND INDICES**

HAEMOGLOBIN (HB) by CALORIMETRIC	11.2 <sup>L</sup>	gm/dL	12.0 - 16.0
RED BLOOD CELL (RBC) COUNT by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	4.17	Millions/cmm	3.50 - 5.00
PACKED CELL VOLUME (PCV) by calculated by automated hematology analyzer	34.6 <sup>L</sup>	%	37.0 - 50.0
MEAN CORPUSCULAR VOLUME (MCV) by calculated by automated hematology analyzer	82.9	fL	80.0 - 100.0
MEAN CORPUSCULAR HAEMOGLOBIN (MCH) by Calculated by automated hematology analyzer	26.8 <sup>L</sup>	pg	27.0 - 34.0
MEAN CORPUSCULAR HEMOGLOBIN CONC. (MCHC) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	32.3	g/dL	32.0 - 36.0
RED CELL DISTRIBUTION WIDTH (RDW-CV) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	13.8	%	11.00 - 16.00
RED CELL DISTRIBUTION WIDTH (RDW-SD) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	42.3	fL	35.0 - 56.0
MENTZERS INDEX by CALCULATED	19.88	RATIO	BETA THALASSEMIA TRAIT: < 13.0 IRON DEFICIENCY ANEMIA: >13.0
GREEN & KING INDEX by CALCULATED	27.37	RATIO	BETA THALASSEMIA TRAIT:<= 65.0 IRON DEFICIENCY ANEMIA: > 65.0
WHITE BLOOD CELLS (WBCS)			
TOTAL LEUCOCYTE COUNT (TLC) by flow cytometry by sf cube & microscopy <b>DIFFERENTIAL LEUCOCYTE COUNT (DLC)</b>	4820	/cmm	4000 - 11000
NEUTROPHILS by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	60	%	50 - 70
LYMPHOCYTES	33	%	20 - 40



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUĞAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



Page 1 of 15

AGE/ GENDER : 35 YRS/FEMALE **PATIENT ID** : 1727178

**COLLECTED BY** REG. NO./LAB NO. : 122501180004

**REFERRED BY REGISTRATION DATE** : 18/Jan/2025 09:26 AM **COLLECTION DATE** BARCODE NO. : 12506569 : 18/Jan/2025 09:27AM REPORTING DATE CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE : 18/Jan/2025 01:39PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
EOSINOPHILS	1	%	1 - 6
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
MONOCYTES	6	%	2 - 12
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY BASOPHILS	0	%	0 - 1
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	U	70	0 - 1
ABSOLUTE LEUKOCYTES (WBC) COUNT			
ABSOLUTE NEUTROPHIL COUNT	2892	/cmm	2000 - 7500
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	1 701	,	000 4000
ABSOLUTE LYMPHOCYTE COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	1591	/cmm	800 - 4900
ABSOLUTE EOSINOPHIL COUNT	48	/cmm	40 - 440
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	40	/ CIIIII	40 - 440
ABSOLUTE MONOCYTE COUNT	289	/cmm	80 - 880
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
ABSOLUTE BASOPHIL COUNT	0	/cmm	0 - 110
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY  DIATELETS AND OTHER DIATELET REPORTS.	MADVEDC		
PLATELETS AND OTHER PLATELET PREDICTIVE			
PLATELET COUNT (PLT)	193000	/cmm	150000 - 450000
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE PLATELETCRIT (PCT)	0.28	%	0.10 - 0.36
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	0.20	70	0.10 - 0.50
MEAN PLATELET VOLUME (MPV)	14 <sup>H</sup>	fL	6.50 - 12.0
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	1-1		
PLATELET LARGE CELL COUNT (P-LCC)	$108000^{H}$	/cmm	30000 - 90000
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	TT	0/	110 450
PLATELET LARGE CELL RATIO (P-LCR) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	56 <sup>H</sup>	%	11.0 - 45.0
PLATELET DISTRIBUTION WIDTH (PDW)	15.7	%	15.0 - 17.0
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	13.7	/0	13.0 - 17.0
NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD			



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS, MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST



**AGE/ GENDER** : 35 YRS/FEMALE **PATIENT ID** :1727178

COLLECTED BY REG. NO./LAB NO. : 122501180004

REFERRED BY **REGISTRATION DATE** : 18/Jan/2025 09:26 AM BARCODE NO. : 12506569 **COLLECTION DATE** : 18/Jan/2025 09:27AM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

**Value** Unit **Biological Reference interval Test Name** 

REPORTING DATE

#### **ERYTHROCYTE SEDIMENTATION RATE (ESR)**

ERYTHROCYTE SEDIMENTATION RATE (ESR)

mm/1st hr

0 - 20

: 18/Jan/2025 02:47PM

by RED CELL AGGREGATION BY CAPILLARY PHOTOMETRY

#### INTERPRETATION:

CLIENT CODE.

1. ESR is a non-specific test because an elevated result often indicates the presence of inflammation associated with infection, cancer and auto-immune disease, but does not tell the health practitioner exactly where the inflammation is in the body or what is causing it.

2. An ESR can be affected by other conditions besides inflammation. For this reason, the ESR is typically used in conjunction with other test such

3. This test may also be used to monitor disease activity and response to therapy in both of the above diseases as well as some others, such as systemic lupus erythematosus

#### CONDITION WITH LOW ESR

A low ESR can be seen with conditions that inhibit the normal sedimentation of red blood cells, such as a high red blood cell count (polycythaemia), significantly high white blood cell count (leucocytosis), and some protein abnormalities. Some changes in red cell shape (such as sickle cells in sickle cell anaemia) also lower the ESR. NOTE:

- ESR and C reactive protein (C-RP) are both markers of inflammation.
   Generally, ESR does not change as rapidly as does CRP, either at the start of inflammation or as it resolves.
   CRP is not affected by as many other factors as is ESR, making it a better marker of inflammation.
   If the ESR is elevated, it is typically a result of two types of proteins, globulins or fibrinogen.
   Women tend to have a higher ESR, and menstruation and pregnancy can cause temporary elevations.
   Drugs such as doutran mathyldona oral contracentives, popicillamino procainamide, the only viling, and vitaliance.

- 6. Drugs such as dextran, methyldopa, oral contraceptives, penicillamine procainamide, theophylline, and vitamin A can increase ESR, while aspirin, cortisone, and quinine may decrease it



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



**AGE/ GENDER** : 35 YRS/FEMALE **PATIENT ID** :1727178

**COLLECTED BY** : 122501180004 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 18/Jan/2025 09:26 AM BARCODE NO. : 12506569 **COLLECTION DATE** : 18/Jan/2025 09:27AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 18/Jan/2025 02:37PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Biological Reference interval Test Name** 

## **CLINICAL CHEMISTRY/BIOCHEMISTRY GLUCOSE FASTING (F)**

GLUCOSE FASTING (F): PLASMA 105.84<sup>H</sup> mg/dL NORMAL: < 100.0

by GLUCOSE OXIDASE - PEROXIDASE (GOD-POD) PREDIABETIC: 100.0 - 125.0 DIABETIC: > 0R = 126.0

INTERPRETATION
IN ACCORDANCE WITH AMERICAN DIABETES ASSOCIATION GUIDELINES:

1. A fasting plasma glucose level below 100 mg/dl is considered normal.

2. A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood

test (after consumption of 75 gms of glucose) is recommended for all such patients.

3. A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients. A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



AGE/ GENDER : 35 YRS/FEMALE **PATIENT ID** : 1727178

**COLLECTED BY** REG. NO./LAB NO. : 122501180004

**REFERRED BY REGISTRATION DATE** : 18/Jan/2025 09:26 AM **COLLECTION DATE** BARCODE NO. : 12506569 : 18/Jan/2025 09:27AM

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 18/Jan/2025 01:39PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
	LIPID PROFILE	: BASIC	
CHOLESTEROL TOTAL: SERUM by CHOLESTEROL OXIDASE PAP	187.08	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)	81.72	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION	31.51	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	139.23 <sup>H</sup>	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	155.57 <sup>H</sup>	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	16.34	mg/dL	0.00 - 45.00
TOTAL LIPIDS: SERUM by CALCULATED, SPECTROPHOTOMETRY	455.88	mg/dL	350.00 - 700.00
CHOLESTEROL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	5.94 <sup>H</sup>	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS, MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST



AGE/ GENDER : 35 YRS/FEMALE **PATIENT ID** :1727178

**COLLECTED BY** : 122501180004 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 18/Jan/2025 09:26 AM BARCODE NO. : 12506569 **COLLECTION DATE** : 18/Jan/2025 09:27AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 18/Jan/2025 01:39PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	4.42 <sup>H</sup>	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	$2.59^{L}$	RATIO	3.00 - 5.00

#### **INTERPRETATION:**

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co-primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



**AGE/ GENDER** : 35 YRS/FEMALE **PATIENT ID** : 1727178

COLLECTED BY : REG. NO./LAB NO. : 122501180004

 REFERRED BY
 : 18/Jan/2025 09:26 AM

 BARCODE NO.
 : 12506569
 COLLECTION DATE
 : 18/Jan/2025 09:27 AM

 CLIENT CODE.
 : P.K.R JAIN HEALTHCARE INSTITUTE
 REPORTING DATE
 : 18/Jan/2025 01:39 PM

**CLIENT ADDRESS**: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Volus	TI-si4	Riological Reference interval
1 est Name	Value	Unit	Biological Reference interval

## **LIVER FUNCTION TEST (COMPLETE)**

BILIRUBIN TOTAL: SERUM by DIAZOTIZATION, SPECTROPHOTOMETRY	0.49	mg/dL	INFANT: 0.20 - 8.00 ADULT: 0.00 - 1.20
BILIRUBIN DIRECT (CONJUGATED): SERUM by DIAZO MODIFIED, SPECTROPHOTOMETRY	0.21	mg/dL	0.00 - 0.40
BILIRUBIN INDIRECT (UNCONJUGATED): SERUM by CALCULATED, SPECTROPHOTOMETRY	0.28	mg/dL	0.10 - 1.00
SGOT/AST: SERUM by IFCC, WITHOUT PYRIDOXAL PHOSPHATE	45.11 <sup>H</sup>	U/L	7.00 - 45.00
SGPT/ALT: SERUM by IFCC, WITHOUT PYRIDOXAL PHOSPHATE	71.94 <sup>H</sup>	U/L	0.00 - 49.00
AST/ALT RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	0.63	RATIO	0.00 - 46.00
ALKALINE PHOSPHATASE: SERUM by Para nitrophenyl phosphatase by amino methyl propanol	106.2	U/L	40.0 - 130.0
GAMMA GLUTAMYL TRANSFERASE (GGT): SERUM by SZASZ, SPECTROPHTOMETRY	20.34	U/L	0.00 - 55.0
TOTAL PROTEINS: SERUM by BIURET, SPECTROPHOTOMETRY	6.66	gm/dL	6.20 - 8.00
ALBUMIN: SERUM by BROMOCRESOL GREEN	3.85	gm/dL	3.50 - 5.50
GLOBULIN: SERUM by CALCULATED, SPECTROPHOTOMETRY	2.81	gm/dL	2.30 - 3.50
A: GRATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	1.37	RATIO	1.00 - 2.00

#### **INTERPRETATION**

NOTE:- To be correlated in individuals having SGOT and SGPT values higher than Normal Referance Range.

**USE**:- Differential diagnosis of diseases of hepatobiliary system and pancreas.

#### **INCREASED:**

DRUG HEPATOTOXICITY	> 2
ALCOHOLIC HEPATITIS	> 2 (Highly Suggestive)
CIRRHOSIS	1.4 - 2.0
INTRAHEPATIC CHOLESTATIS	> 1.5
HEPATOCELLULAR CARCINOMA & CHRONIC HEPATITIS	> 1.3 (Slightly Increased)



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)



Page 7 of 15

**AGE/ GENDER** : 35 YRS/FEMALE **PATIENT ID** : 1727178

COLLECTED BY : REG. NO./LAB NO. : 122501180004

 REFERRED BY
 : 18/Jan/2025 09:26 AM

 BARCODE NO.
 : 12506569
 COLLECTION DATE
 : 18/Jan/2025 09:27 AM

 CLIENT CODE.
 : P.K.R JAIN HEALTHCARE INSTITUTE
 REPORTING DATE
 : 18/Jan/2025 01:39 PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit Biological Reference interval

#### **DECREASED:**

1. Acute Hepatitis due to virus, drugs, toxins (with AST increased 3 to 10 times upper limit of normal)

2. Extra Hepatic cholestatis: 0.8 (normal or slightly decreased).

#### PROGNOSTIC SIGNIFICANCE:

NORMAL	< 0.65
GOOD PROGNOSTIC SIGN	0.3 - 0.6
POOR PROGNOSTIC SIGN	1.2 - 1.6



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUĞAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



Page 8 of 15

**AGE/ GENDER** : 35 YRS/FEMALE **PATIENT ID** : 1727178

COLLECTED BY : REG. NO./LAB NO. : 122501180004

 REFERRED BY
 :
 REGISTRATION DATE
 : 18/Jan/2025 09:26 AM

 BARCODE NO.
 : 12506569
 COLLECTION DATE
 : 18/Jan/2025 09:27AM

**CLIENT CODE.** : P.K.R JAIN HEALTHCARE INSTITUTE **REPORTING DATE** : 18/Jan/2025 01:39PM

**CLIENT ADDRESS**: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
KIDNI	EY FUNCTION TI	EST (COMPLETE)	
UREA: SERUM by urease - glutamate dehydrogenase (gldh)	40.56	mg/dL	10.00 - 50.00
CREATININE: SERUM by ENZYMATIC, SPECTROPHOTOMETERY	0.96	mg/dL	0.40 - 1.20
BLOOD UREA NITROGEN (BUN): SERUM by CALCULATED, SPECTROPHOTOMETRY	18.95	mg/dL	7.0 - 25.0
BLOOD UREA NITROGEN (BUN)/CREATININE RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	19.74	RATIO	10.0 - 20.0
UREA/CREATININE RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	42.25	RATIO	
URIC ACID: SERUM by URICASE - OXIDASE PEROXIDASE	3.22	mg/dL	2.50 - 6.80
CALCIUM: SERUM by ARSENAZO III, SPECTROPHOTOMETRY	9.29	mg/dL	8.50 - 10.60
PHOSPHOROUS: SERUM by PHOSPHOMOLYBDATE, SPECTROPHOTOMETRY	2.97	mg/dL	2.30 - 4.70
ELECTROLYTES  SODIUM: SERUM by ISE (ION SELECTIVE ELECTRODE)	141.2	mmol/L	135.0 - 150.0
POTASSIUM: SERUM by ISE (ION SELECTIVE ELECTRODE)	4.5	mmol/L	3.50 - 5.00
CHLORIDE: SERUM by ISE (ION SELECTIVE ELECTRODE)	105.9	mmol/L	90.0 - 110.0
ESTIMATED GLOMERULAR FILTERATION RATE			

ESTIMATED GLOMERULAR FILTERATION RATE 79.1

(eGFR): SERUM
by CALCULATED

### INTERPRETATION:

To differentiate between pre- and post renal azotemia.

#### INCREASED RATIO (>20:1) WITH NORMAL CREATININE:

- 1. Prerenal azotemia (BUN rises without increase in creatinine) e.g. heart failure, salt depletion, dehydration, blood loss) due to decreased glomerular filtration rate.
- 2. Catabolic states with increased tissue breakdown.
- 3. GI haemorrhage.



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)



Page 9 of 15

AGE/ GENDER : 35 YRS/FEMALE **PATIENT ID** :1727178

**COLLECTED BY** : 122501180004 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 18/Jan/2025 09:26 AM BARCODE NO. : 12506569 **COLLECTION DATE** : 18/Jan/2025 09:27AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 18/Jan/2025 01:39PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Test Name Value** Unit **Biological Reference interval** 

4. High protein intake.

5. Impaired renal function plus

6. Excess protein intake or production or tissue breakdown (e.g. infection, GI bleeding, thyrotoxicosis, Cushing's syndrome, high protein diet, burns, surgery, cachexia, high fever).

7. Urine reabsorption (e.g. ureter colostomy)

8. Reduced muscle mass (subnormal creatinine production)

9. Certain drugs (e.g. tetracycline, glucocorticoids)

#### INCREASED RATIO (>20:1) WITH ELEVATED CREATININE LEVELS:

- 1. Postrenal azotemia (BUN rises disproportionately more than creatinine) (e.g. obstructive uropathy).
- 2. Prerenal azotemia superimposed on renal disease.

#### DECREASED RATIO (<10:1) WITH DECREASED BUN:

- 1. Acute tubular necrosis.
- 2. Low protein diet and starvation.
- 3. Severe liver disease.
- 4. Other causes of decreased urea synthesis.
- 5. Repeated dialysis (urea rather than creatinine diffuses out of extracellular fluid).
- 6. Inherited hyperammonemias (urea is virtually absent in blood).
- 7. SIADH (syndrome of inappropiate antidiuretic harmone) due to tubular secretion of urea.
- 8. Pregnancy.

#### **DECREASED RATIO (<10:1) WITH INCREASED CREATININE:**

- 1. Phenacimide therapy (accelerates conversion of creatine to creatinine).
- 2. Rhabdomyolysis (releases muscle creatinine).
- 3. Muscular patients who develop renal failure.

#### **INAPPROPIATE RATIO:**

- 1. Diabetic ketoacidosis (acetoacetate causes false increase in creatinine with certain methodologies, resulting in normal ratio when dehydration should produce an increased BUN/creatinine ratio).
- 2. Cephalosporin therapy (interferes with creatinine measurement). **ESTIMATED GLOMERULAR FILTERATION RATE**:

CKD STAGE	DESCRIPTION	GFR ( mL/min/1.73m2 )	ASSOCIATED FINDINGS
G1	Normal kidney function	>90	No proteinuria
G2	Kidney damage with normal or high GFR	>90	Presence of Protein , Albumin or cast in urine
G3a	Mild decrease in GFR	60 -89	
G3b	Moderate decrease in GFR	30-59	
G4	Severe decrease in GFR	15-29	
G5	Kidney failure	<15	



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



AGE/ GENDER : 35 YRS/FEMALE **PATIENT ID** :1727178

**COLLECTED BY** : 122501180004 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 18/Jan/2025 09:26 AM BARCODE NO. : 12506569 **COLLECTION DATE** : 18/Jan/2025 09:27AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 18/Jan/2025 01:39PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Test Name Value** Unit **Biological Reference interval** 

#### COMMENTS:

1. Estimated Glomerular filtration rate (eGFR) is the sum of filtration rates in all functioning nephrons and so an estimation of the GFR provides a measure of functioning nephrons of the kidney.

2. eGFR calculated using the 2009 CKD-EPI creatinine equation and GFR category reported as per KDIGO guideline 2012

3. In patients, with eGFR creatinine between 45-59 ml/min/1.73 m2 (G3) and without any marker of Kidney damage, It is recommended to measure eGFR with Cystatin C for confirmation of CKD

eGFR should be calculated using Serum Cystatin C
7. A decrease in eGFR implies either progressive renal disease, or a reversible process causing decreased nephron function (eg, severe dehydration). ADVICE:

KDIGO guideline, 2012 recommends Chronic Kidney Disease (CKD) should be classified based on cause, eGFR category and Albuminuria (ACR) category. GFR & ACR category combined together reflect risk of progression and helps Clinician to identify the individual who are progressing at more rapid rate than anticipated



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



**AGE/ GENDER** : 35 YRS/FEMALE **PATIENT ID** : 1727178

COLLECTED BY : REG. NO./LAB NO. : 122501180004

**REFERRED BY**: REGISTRATION DATE: 18/Jan/2025 09:26 AM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit Biological Reference interval

# ENDOCRINOLOGY THYROID FUNCTION TEST: TOTAL

TRIIODOTHYRONINE (T3): SERUM by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)	1.32	ng/mL	0.35 - 1.93
THYROXINE (T4): SERUM by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)	9.78	μgm/dL	4.87 - 12.60
THYROID STIMULATING HORMONE (TSH): SERUM by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)	2.73	μIU/mL	0.35 - 5.50

3rd GENERATION, ULTRASENSITIVE

#### INTERPRETATION:

TSH levels are subject to circadian variation, reaching peak levels between 2-4 a.m and at a minimum between 6-10 pm. The variation is of the order of 50%. Hence time of the day has influence on the measured serum TSH concentrations. TSH stimulates the production and secretion of the metabolically active hormones, thyroxine (T4) and triiodothyronine (T3). Failure at any level of regulation of the hypothalamic-pituitary-thyroid axis will result in either underproduction (hypothyroidism) or overproduction (hyperthyroidism) of T4 and/or T3.

CLINICAL CONDITION	Т3	T4	TSH
Primary Hypothyroidism:	Reduced	Reduced	Increased (Significantly)
Subclinical Hypothyroidism:	Normal or Low Normal	Normal or Low Normal	High
Primary Hyperthyroidism:	Increased	Increased	Reduced (at times undetectable)
Subclinical Hyperthyroidism:	Normal or High Normal	Normal or High Normal	Reduced

#### LIMITATIONS:

- 1. T3 and T4 circulates in reversibly bound form with Thyroid binding globulins (TBG), and to a lesser extent albumin and Thyroid binding Pre Albumin so conditions in which TBG and protein levels alter such as pregnancy, excess estrogens, anabolic steroids and glucocorticoids may falsely affect the T3 and T4 levels and may cause false thyroid values for thyroid function tests.
- 2. Normal levels of T4 can also be seen in Hyperthyroid patients with :T3 Thyrotoxicosis, Decreased binding capacity due to hypoproteinemia or ingestion of certain drugs (e.g.: phenytoin, salicylates)
- 3. Serum T4 levels in neonates and infants are higher than values in the normal adult, due to the increased concentration of TBG in neonate serum.
- 4. TSH may be normal in central hypothyroidism, recent rapid correction of hyperthyroidism or hypothyroidism, pregnancy, phenytoin therapy.

TRIIODOTHYRONINE (T3)		THYROXINE (T4)		THYROID STIMULATING HORMONE (TSH)	
Age	Refferance Range (ng/mL)	Age	Refferance Range (µg/dL)	Age	Reference Range ( μIU/mL)
0-7 Days	0.20 - 2.65	0 - 7 Days	5.90 - 18.58	0 - 7 Days	2.43 - 24.3
7 Days - 3 Months	0.36 - 2.59	7 Days - 3 Months	6.39 - 17.66	7 Days - 3 Months	0.58 - 11.00
3 - 6 Months	0.51 - 2.52	3 - 6 Months	6.75 – 17.04	3 Days – 6 Months	0.70 - 8.40
6 - 12 Months	0.74 - 2.40	6 - 12 Months	7.10 – 16.16	6 – 12 Months	0.70 - 7.00



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)



age 12 of 15

**AGE/ GENDER** : 35 YRS/FEMALE **PATIENT ID** : 1727178

COLLECTED BY : REG. NO./LAB NO. : 122501180004

 REFERRED BY
 : 18/Jan/2025 09:26 AM

 BARCODE NO.
 : 12506569

 COLLECTION DATE
 : 18/Jan/2025 09:27 AM

**CLIENT ADDRESS**: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Test Name			Value	Unit		Biolog	gical Reference interval
1 - 10 Years	0.92 - 2.28	1 - 10 Years	6.00 - 13.80	1 – 10 Years	0.60 - 5.50		
11- 19 Years	0.35 - 1.93	11 - 19 Years	4.87- 13.20	11 – 19 Years	0.50 - 5.50		
> 20 years (Adults)	0.35 - 1.93	> 20 Years (Adults)	4.87 - 12.60	> 20 Years (Adults)	0.35- 5.50		
RECOMMENDATIONS OF TSH LEVELS DURING PREGNANCY ( μιυ/ml)							
1st Trimester			0.10 - 2.50				
2nd Trimester			0.20 - 3.00				
3rd Trimester			0.30 - 4.10				

REPORTING DATE

: 18/Jan/2025 01:39PM

#### **INCREASED TSH LEVELS:**

CLIENT CODE.

- 1. Primary or untreated hypothyroidism may vary from 3 times to more than 100 times normal depending upon degree of hypofunction.
- 2. Hypothyroid patients receiving insufficient thyroid replacement therapy.
- 3. Hashimotos thyroiditis
- 4.DRUGS: Amphetamines, iodine containing agents & dopamine antagonist.
- 5. Neonatal period, increase in 1st 2-3 days of life due to post-natal surge

#### **DECREASED TSH LEVELS:**

- 1. Toxic multi-nodular goiter & Thyroiditis.
- 2. Over replacement of thyroid hormone in treatment of hypothyroidism.
- 3. Autonomously functioning Thyroid adenoma
- 4. Secondary pituitary or hypothalamic hypothyroidism
- 5. Acute psychiatric illness
- 6. Severe dehydration.
- 7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.
- 8. Pregnancy: 1st and 2nd Trimester



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



Page 13 of 15

**AGE/ GENDER** : 35 YRS/FEMALE **PATIENT ID** : 1727178

COLLECTED BY : REG. NO./LAB NO. : 122501180004

 REFERRED BY
 :
 REGISTRATION DATE
 : 18/Jan/2025 09:26 AM

 BARCODE NO.
 : 12506569
 COLLECTION DATE
 : 18/Jan/2025 09:27AM

**CLIENT CODE.** : P.K.R JAIN HEALTHCARE INSTITUTE **REPORTING DATE** : 18/Jan/2025 01:39PM

**CLIENT ADDRESS**: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit Biological Reference interval

# CLINICAL PATHOLOGY URINE ROUTINE & MICROSCOPIC EXAMINATION

#### **PHYSICAL EXAMINATION**

QUANTITY RECIEVED	25	ml
by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY		

COLOUR YELLOW PALE YELLOW

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

TRANSPARANCY HAZY CLEAR

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

SPECIFIC GRAVITY

1.02

1.002 - 1.030

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

#### **CHEMICAL EXAMINATION**

REACTION ACIDIC by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

PROTEIN NEGATIVE (-ve) NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

SUGAR NEGATIVE (-ve) NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

pH 5.5 5.0 - 7.5 by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

BILIRUBIN NEGATIVE (-ve) NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

NITRITE NEGATIVE (-ve) NEGATIVE (-ve)

UROBILINOGEN NOT DETECTED EU/dL 0.2 - 1.0

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

KETONE BODIES

NEGATIVE (-ve)

NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

BLOOD NEGATIVE (-ve) NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

ASCORBIC ACID

NEGATIVE (-ve)

NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

MICROSCOPIC EXAMINATION

RED BLOOD CELLS (RBCs) NEGATIVE (-ve) /HPF 0 - 3



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



Page 14 of 15

AGE/ GENDER : 35 YRS/FEMALE **PATIENT ID** : 1727178

**COLLECTED BY** REG. NO./LAB NO. : 122501180004

REFERRED BY REGISTRATION DATE : 18/Jan/2025 09:26 AM BARCODE NO. **COLLECTION DATE** : 12506569 : 18/Jan/2025 09:27AM CLIENT CODE. REPORTING DATE : P.K.R JAIN HEALTHCARE INSTITUTE : 18/Jan/2025 01:39PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT		_	
PUS CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	3-5	/HPF	0 - 5
EPITHELIAL CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	8-10	/HPF	ABSENT
CRYSTALS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
CASTS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
BACTERIA by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
OTHERS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
TRICHOMONAS VAGINALIS (PROTOZOA) by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	ABSENT		ABSENT

\*\*\* End Of Report \*\*\*



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

